Remove Books Remove Communication Remove FDA
article thumbnail

Innovative Solutions in Healthcare Marketing

Pharma Marketing Network

As we dive deeper into 2025, the convergence of digital technology, patient-centric strategies, and precision targeting is redefining how pharma brands communicate with both healthcare professionals and patients. The pace of transformation in healthcare marketing has accelerated dramatically in recent years.

article thumbnail

The Importance of Modernizing Your Email Marketing Campaigns

Pharma Marketing Network

This ensures consistent communication without overburdening your team. Fortunately, modern email marketing platforms come equipped with features that help ensure every message aligns with HIPAA, CAN-SPAM, and FDA guidelines. Most enterprise platforms offer features to meet HIPAA and FDA compliance requirements when properly configured.

HIPAA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Pharmacy Times

But together, they contribute to the ever-expanding expectation that oncology pharmacists should “know all the things,” an emotion aptly captured by Allie Brosh in her book Hyperbole and a Half. Touchstone Books; 2013. However, one person cannot do all these things well. Time Enough for Love. Putnam’s Sons; 1973.

article thumbnail

Top 10 RPM Vendors 2025: Driving Results in Remote Patient Monitoring

PharmD Live

Full-Spectrum, CMS-Aligned Services: Seamless EHR integration, FDA-cleared devices, real-time alerts, and actionable dashboards ensure providers are audit-ready and financially optimized. Book a Demo with PharmD Live Today References: PharmD Live. Ready to see how pharmacist-led, AI-powered RPM drives measurable results?

HIPAA 52
article thumbnail

Barriers are limiting UK childhood vaccination, say doctors

pharmaphorum

The analysis by the Royal College of Paediatrics and Child Health suggests the main barriers to access are factors like hard-to-book and limited appointments, difficulties in attending clinics, a lack of continuity in care, and a lack of reminders for jabs.

article thumbnail

To List or Not to List; That is the Question – The FTC Signals the Potential for Greater Scrutiny of Patent Information Submissions to FDA

The FDA Law Blog

Karst — Listing patent information in the Orange Book is a matter of judgment, but that judgment call is about to get a bit more scrutiny. Last week, the FTC held a Listening Session about the listing of patents in the Orange Book, which concluded with a unanimous vote to issue a Policy Statement.

FDA 106
article thumbnail

Aduhelm approval controversy dials up as FDA seeks probe

pharmaphorum

In another twist to the Aduhelm approval tale, FDA’s Janet Woodcock has called for an independent investigation into the relationship between agency staffers and Biogen executives. In the letter, she writes: “FDA’s decisions are far ranging and it is inevitable that some of those decisions will lead to controversy.”

FDA 52